中文ENGLISH
分享到 

About Haisco

HOME > About haisco > subsidiary profile

关于海思科

关于海思科

Subsidiary introduction

Liaoning Haisco Pharmaceutical Co., Ltd.

Established on May 19, 2005, Liaoning Haisco Pharmaceutical Co., Ltd. was approved as a national high-tech enterprise in July 2011. Liaoning Haisco possesses more than 100,000m2 of various types of plant buildings and supporting facilities in compliance with the national GMP standards, and 11 professional production lines for small volume injection, large volume injection (glass bottles), large volume injection (non PVC soft bag), freeze-dried powder injection (containing hormones), cephalosporin sterile powder injection, bulk drug.

 

Liaoning Haisco always attaches importance to the development of new products. So far, it has obtained 22 approval documents for the production of drugs, including nalmefene hydrochloride injection, dolasetron mesylate injection, cefodizime sodium for injection, hydroxyethyl starch 200/0.5 and sodium chloride injection, medium and long chain fat emulsion injection(C8-24),compound amino acids injection (18AA-VII).

 



Sichuan Haisco Pharmaceutical Co., Ltd.

Established in August 2007, Sichuan Haisco Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Tibet Haisco Pharmaceutical Group Co., Ltd., located at Cross-Strait Science & Technology Park, Wenjiang District, Chengdu, covering a land area of 33,266m2, with registered capital of CNY 20,000,000. The products of the company are widely involved in the fields such as cardiovascular, anti-infection, digestive system, nervous & mental system, hepatopathy, diabetes mellitus, etc. The company is the exclusive manufacturer or one of few manufacturers of many products. The company possesses multiple production lines for producing capsules, tablets, granules, and bulk drugs. 

 

Over 20 new drugs are in the reporting period, including the field of cardiovascular, anti-infection, digestive system, nervous & mental system, hepatopathy, diabetes mellitus, etc. The company bases itself on the provision of the latest and high-quality drugs to the domestic patients. Relying on the opportunity of the implementation of new GMP, Sichuan Haisco endeavors to construct the enterprise into a domestic top modern pharmaceutical R&D and production base in compliance with the standards of the U.S. FDA and the EU cGMP. Sichuan Haisco Pharmaceutical Co., Ltd. is an energetic enterprise growing rapidly. The Haisco people will attain greater achievements on this fertile land.